Tumor Ablation Market: Growth, Size, Share, and Trends

Tumor Ablation Market by Technology (Radiofrequency, Microwave, Laser, IRE, HIFU, Cryoablation), Product (Generators, Probes), Mode (Surgical, Laparoscopic, Percutaneous), Cancer (Liver, Lung, Bone), End User (Hospitals, Clinic) & Region - Global Forecast to 2029

Report Code: MD 3271 May, 2024, by marketsandmarkets.com

Market Growth Outlook Summary

The global tumor ablation market, valued at US$0.7 billion in 2023, is forecasted to grow at a robust CAGR of 10.0%, reaching US$0.8 billion in 2024 and an impressive US$1.4 billion by 2029. Over the years, the ablation technology have evolved significantly, with a focus on improved reliability, real-time monitoring, and faster recovery. These innovations, combined with increasing cancer incidence rates and the need for improved treatment, have driven the growth of the market. As healthcare advances, tumor ablation systems contribute to enhaced and first line treatment for benign tumors. The use of tumor ablation systems for various applications continues to drive innovation and breakthroughs in various domains, benefiting humanity in numerous ways.

Tumor Ablation Market Trends

Tumor Ablation Market

To know about the assumptions considered for the study, Request for Free Sample Report

Tumor Ablation Market

e- Estimated; p- Projected

Tumor Ablation Market Dynamics

Driver: Increasing cancer incidence and rising geriatric population

Tumor ablation market is primarily driven by the rising incidence of cancer globally. Tumor ablation is widely used for the treatment of lung cancer, liver cancer, prostate cancer, bone cancer, and kidney cancer among others. According to WHO, cancer was the major cause of death globally in 2020 -accounted for around 10 mn deaths. Emerging economies in Asia, Africa, and Oceania reported 55% of the 18.1 million cancer cases diagnosed. With the continuous rise in the global cancer patient population, there is expected to be a significant increase in demand for tumor ablation procedures during the forecast period.

Restraint: Increasing cancer incidence and rising geriatric population

High cost of tumor ablation systems is one of the restrains in tumor ablation market. Premium product pricing hinders the adoption in emerging countries. Small healthcare facilities rely on third-party payers to reimburse the costs incurred in diagnostic, screening, and therapeutic procedures. The high cost of the equipment makes it difficult for most hospitals in emerging economies to afford this technology. Hence, smaller end users are hesitant to invest in this equipment.

Opportunity: Rising healthcare expenditure across emerging economies

Growing healthcare expenditure in emerging nations such as China, India, Brazil, and Mexico are expected to offer lucrative opportunities for tumor ablation market. For instance, according to GLOBOCAN 2020 data, over 50% of the global cancer population resides in emerging economies. Increasing government initiatives towards providing advanced healthcare services and improving reimbursement coverage support the adoption of tumor ablation devices. rapid increase in the per-capita healthcare expenditure and the rising public demand for affordable healthcare in emerging economies to further expected to drive the demand for ablation systems in developing countries.

Challenge: Rising adoption of refurbished tumor ablation systems

Small scale end users specifically in developing countries often opt for refurbished alternatives as a cost-effective solution. Refurbished systems are sold at a fraction of the cost of new equipment Refurbished systems are sold at a fraction of the cost of new equipment. Due to similar functioning and affordable cost the adoption of refurbished systems is experiencing a surge in the adoption. This poses a challenge for smaller manufacturers who are struggling to keep up and is expected to impact the market growth.

Tumor Ablation Industry Ecosystem.

Tumor Ablation Market Ecosystem

By Technology, the radiofrequency ablation segment accounted for the largest share of the tumor ablation industry.

Based on technology, the tumor ablation market is segmented into radiofrequency ablation, microwave ablation, high intensity focused ultrasound (HIFU), cryoablation, and other technologies. In 2023, the radiofrequency ablation segment accounted for the largest market share. Rising awareness of proactive health and expansion of market players fuel the growth of tumor ablation market.

By Product Type, the generators segment of the tumor ablation industry to register significant growth in the near future.

Based on product type, the tumor ablation market is segmented into generators probes and electrodes. The generators segment accounted for the largest market share in 2023. The demand for minimally invasive procedures is increasing due to the emphasis on improving quality of life. Additionally, favorable regulatory scenarios and a surge in oncological surgeries contribute to the rising adoption of tumor ablation systems.

The laparoscopic ablation segment for mode of treatment segment is expected to register a higher CAGR of the tumor ablation industry forecast period.

Based on mode of treatment, the tumor ablation market is segmented into laparoscopic ablation, surgical ablation, and percutaneous ablation. Increasing collaboration between industry players and healthcare providers and integration of ablation systems with other treatment modalities contribute to the growth of this segment. Laparoscopic ablation has improved benefits as compared to other modes of treamtnets. Factors such as reduced pain, greater visibility due to laparoscopic cameras, quick recovery, and shorter stays at the hospitals contribute to the exponential growth of this segment.

The liver cancer segment for application segment held the largest share of the tumor ablation industry.

Based on application, the tumor ablation market is segmented into liver cancer, kidney cancer, lung cancer, bone cancer, and other applications. Liver cancer segment held largest share of the market in 2023 and is also expected to register a significant growth rate from 2024 to 2029. Increasing adoption of image-guided therapies and increasing funding opportunities for cancer research are driving the adoption.

By end user, the hospitals and clinic centers segment of the tumor ablation industry held the largest share.

The tumor ablation market is segmented by end users into hospitals and clinics, cancer care centers, and other end users. However, the cancer care centers segment is expected to grow at the highest CAGR during the forecast period.  The rise in number of chronic diseases, including cancer, increasing cancer diagnostic procedures in the hospitals globally, and the potential of benefits of ablation observed in patients with early stage cancer have contributed to the growth of this segment.

By region, North America is expected to be the largest market of the tumor ablation industry by 2029.

The US and Canada accounted for a significant market share in 2023. North America's faster growth in the tumor ablation market can be attributed to its technological leadership, robust healthcare infrastructure, favorable insurance coverage, growing funding and grants for developing advanced medical equipment, favorable regulatory scenario, strategic research collaboration, and a supportive market environment fostering innovation.

Tumor Ablation Market by Region

To know about the assumptions considered for the study, download the pdf brochure

As of 2023, prominent players in the market are Johnson & Johnson MedTech (US), Medtronic Plc (Ireland), Stryker Corporation (US), Varian Medical Systems, Inc. (US), Olympus (Japan), AngioDynamics, Inc. (US), Boston Scientific Corporation (US), IceCure Medical Ltd. (Israel), Bioventus Inc. (US).

Tumor Ablation Market Report Scope

Report Metric

Details

Market Revenue in 2024

$0.8 billion

Projected Revenue by 2029

$1.4 billion

Revenue Rate

Poised to Grow at a CAGR of 10.0%

Market Driver

Increasing cancer incidence and rising geriatric population

Market Opportunity

Rising healthcare expenditure across emerging economies

This report has segmented the global tumor ablation market to forecast revenue and analyze trends in each of the following submarkets:

By Technology

  • Radiofrequency Ablation
  • Microwave Ablation
  • Cryoablation
  • High-intensity Focused Ultrasound
  • Other Technologies

By Product Type

  • Generators
  • Probes/electrodes

By Mode Of Treatment

  • Surgical Ablation
  • Percutaneous Ablation
  • Laparoscopic Ablation

By Application

  • Liver Cancer
  • Lung Cancer
  • Kidney Cancer
  • Bone Cancer
  • Other Applications

By End User

  • Hospitals & clinics
  • Cancer care centers
  • Other End Users

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America

Recent Developments of the Tumor Ablation Market

  • In May 2023, Varian launched the Isolis cryoprobe for CryoCare systems. These are disposable probes with improved efficiency and precision for cryoablation. It helps with tumor ablation. They also support accuracy and help to reduce procedure time.
  • In April 2023, AngioDynamics extended its partnership with Cardiva. The collaboration aims to introduce AngioDynamics’ oncology products across Europe.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

INTRODUCTION
21
RESEARCH METHODOLOGY
25
EXECUTIVE SUMMARY
37
PREMIUM INSIGHTS
41
MARKET OVERVIEW
44
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Increasing cancer incidence and rising geriatric population
    - Rising focus on minimally invasive procedures
    - Technological advancements in field of tumor ablation
    - Rising number of awareness campaigns and early detection
    RESTRAINTS
    - High cost of tumor ablation systems
    - Unfavorable regulatory scenario
    OPPORTUNITIES
    - Rising healthcare expenditure across emerging economies
    - Increasing number of hospitals
    CHALLENGES
    - Rising adoption of refurbished tumor ablation systems
    - Hospital budget cuts
  • 5.3 REGULATORY ANALYSIS
    KEY REGULATORY BODIES AND GOVERNMENT AGENCIES
    KEY REGULATORY GUIDELINES
    - US
    - Canada
    - Europe
    - Asia Pacific
    - Latin America
  • 5.4 REIMBURSEMENT SCENARIO
  • 5.5 VALUE CHAIN ANALYSIS
    RESEARCH & DEVELOPMENT
    MANUFACTURING & ASSEMBLY
    DISTRIBUTION, MARKETING & SALES, AND POST-SALES SERVICES
  • 5.6 SUPPLY CHAIN ANALYSIS
    PROMINENT COMPANIES
    SMALL AND MEDIUM-SIZED ENTERPRISES
    END USERS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT & FUNDING SCENARIO
  • 5.9 PRICING ANALYSIS
  • 5.10 TRADE ANALYSIS
  • 5.11 PATENT ANALYSIS
  • 5.12 PORTER’S FIVE FORCE ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.13 KEY CONFERENCES & EVENTS IN 2024–2025
  • 5.14 CASE STUDY ANALYSIS
  • 5.15 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Radiofrequency ablation and microwave ablation
    - Cryoablation
    COMPLEMENTARY TECHNOLOGIES
    - Laparoscopy
    - Diagnostic imaging
    ADJACENT TECHNOLOGIES
    - Electrosurgery
  • 5.16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.17 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.18 UNMET NEEDS & KEY PAIN POINTS
TUMOR ABLATION MARKET, BY TECHNOLOGY
74
  • 6.1 INTRODUCTION
  • 6.2 RADIOFREQUENCY ABLATION
    LOW COST OF RADIOFREQUENCY ABLATION TO CONTRIBUTE TO MARKET GROWTH
  • 6.3 MICROWAVE ABLATION
    ADVANTAGES OF MICROWAVE ABLATION TO BOOST MARKET GROWTH
  • 6.4 CRYOABLATION
    HIGH SAFETY AND EFFICACY OF CRYOABLATION TO BOOST MARKET
  • 6.5 HIGH-INTENSITY-FOCUSED ULTRASOUND (HIFU)
    TECHNOLOGICAL ADVANCEMENTS IN ULTRASOUND ABLATION TO FAVOR MARKET GROWTH
  • 6.6 OTHER TECHNOLOGIES
TUMOR ABLATION MARKET, BY PRODUCT TYPE
80
  • 7.1 INTRODUCTION
  • 7.2 GENERATORS
    RISING ADOPTION OF TUMOR ABLATION SYSTEMS TO PROPEL MARKET GROWTH
  • 7.3 PROBES/ELECTRODES
    RADIOFREQUENCY ABLATION PROBES
    - Rising adoption of radiofrequency ablation systems for multiple applications to propel market growth
    MICROWAVE ABLATION PROBES
    - Increasing cancer prevalence and precise ablation to boost adoption
    OTHER PROBES/ELECTRODES
TUMOR ABLATION MARKET, BY MODE OF TREATMENT
85
  • 8.1 INTRODUCTION
  • 8.2 SURGICAL ABLATION
    RISING UTILIZATION OF SURGICAL ABLATION IN END-USER FACILITIES TO PROPEL MARKET
  • 8.3 LAPAROSCOPIC ABLATION
    IMPROVED SUCCESS RATE AND REAL-TIME VISUALIZATION TO BOOST DEMAND
  • 8.4 PERCUTANEOUS ABLATION
    SHORTER RECOVERY TIME AND COST-EFFECTIVENESS OF PROCEDURE TO DRIVE SEGMENT
TUMOR ABLATION MARKET, BY APPLICATION
90
  • 9.1 INTRODUCTION
  • 9.2 LIVER CANCER
    PROMISING OUTCOMES OF ABLATION IN TREATING HCC TO DRIVE MARKET
  • 9.3 LUNG CANCER
    RISING INCIDENCE OF LUNG CANCER TO FUEL MARKET
  • 9.4 KIDNEY CANCER
    RISING PREVALENCE OF KIDNEY CANCER AND MINIMAL DAMAGE OF HEALTHY TISSUE TO DRIVE ADOPTION
  • 9.5 BONE CANCER
    RISING USE OF ABLATION TECHNIQUES TO TREAT OSTEOID OSTEOMA TO BOOST GROWTH
  • 9.6 OTHER APPLICATIONS
TUMOR ABLATION MARKET, BY END USER
95
  • 10.1 INTRODUCTION
  • 10.2 HOSPITALS & CLINICS
    INCREASING ADOPTION OF ADVANCED TUMOR ABLATION SYSTEMS TO PROPEL MARKET
  • 10.3 CANCER CARE CENTERS
    GROWING ESTABLISHMENT OF CANCER CARE CENTERS TO FUEL MARKET
  • 10.4 OTHER END USERS
TUMOR ABLATION MARKET, BY REGION
99
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    NORTH AMERICA: RECESSION IMPACT
    US
    - Rising prevalence of cancer to propel market growth
    CANADA
    - Growing burden of cancer to support market growth
  • 11.3 EUROPE
    EUROPE: RECESSION IMPACT
    GERMANY
    - Highly developed healthcare infrastructure and rising disease incidence to ensure strong growth prospects
    FRANCE
    - Growing geriatric population to support market growth in France
    UK
    - Growing target patient population to support market growth in UK
    ITALY
    - Rising awareness to support market growth
    SPAIN
    - Increasing government funding for research to support market growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
    JAPAN
    - Presence of universal healthcare reimbursement scenario to drive market growth
    CHINA
    - Increasing patient pool and government initiatives for healthcare development to fuel market growth
    INDIA
    - Ongoing modernization and infrastructure development in India to support market growth
    AUSTRALIA
    - Rising research investments and awareness campaigns to support market growth
    SOUTH KOREA
    - Rising R&D and promising clinical trials to positively impact market growth
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    LATIN AMERICA: RECESSION IMPACT
    BRAZIL
    - Modernization of healthcare facilities in Brazil to boost market
    MEXICO
    - Availability of advanced care and increasing awareness programs to fuel market growth in Mexico
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH
    MIDDLE EAST & AFRICA: RECESSION IMPACT
COMPETITIVE LANDSCAPE
127
  • 12.1 OVERVIEW
  • 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN TUMOR ABLATION MARKET
  • 12.3 REVENUE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2023
    - Company footprint
    - Technology footprint
    - Region footprint
  • 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 12.7 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 12.8 BRAND/PRODUCT COMPARISON
  • 12.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES/APPROVALS
    DEALS
    EXPANSIONS
COMPANY PROFILES
142
  • 13.1 KEY PLAYERS
    MEDTRONIC PLC
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    JOHNSON & JOHNSON MEDTECH (ETHICON)
    - Business overview
    - Products offered
    - MnM view
    STRYKER CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    VARIAN MEDICAL SYSTEMS, INC.
    - Business overview
    - Products offered
    - Recent developments
    ANGIODYNAMICS, INC.
    - Business overview
    - Products offered
    - Recent developments
    BOSTON SCIENTIFIC CORPORATION
    - Business overview
    - Products offered
    EDAP TMS S.A.
    - Business overview
    - Products offered
    MERMAID MEDICAL
    - Business overview
    - Products offered
    CANYON MEDICAL INC.
    - Business overview
    - Products offered
    OLYMPUS CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.
    - Business overview
    - Products offered
    MERIT MEDICAL SYSTEMS, INC.
    - Business overview
    - Products offered
    BIOVENTUS INC.
    - Business overview
    - Products offered
    - Recent developments
    ICECURE MEDICAL LTD.
    - Business overview
    - Products offered
    - Recent developments
    CONMED CORPORATION
    - Business overview
    - Products offered
  • 13.2 OTHER PLAYERS
    MONTERIS MEDICAL
    MIANYANG SONIC ELECTRONIC
    RF MEDICAL
    MINIMAX MEDICAL HOLDING GROUP
    SONABLATE
    ECO MEDICAL TECHNOLOGY (NANJING) CO., LTD.
    STARMED CO., LTD.
    SURGNOVA
    CREO MEDICAL
    MEDSPHERE SHANGHAI
APPENDIX
184
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 NORTH AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 2 EUROPE: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 3 ASIA PACIFIC: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 4 LATIN AMERICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 5 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES AND GOVERNMENT AGENCIES
  • TABLE 6 US FDA: MEDICAL DEVICE CLASSIFICATION
  • TABLE 7 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 8 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS
  • TABLE 9 JAPAN: PMDA CLASSIFICATION OF ABLATION DEVICES
  • TABLE 10 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PHARMACEUTICAL AND MEDICAL DEVICE AGENCY (PMDA)
  • TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 12 INDIA: CDSCO CLASSIFICATION OF ABLATION DEVICES
  • TABLE 13 MEDICAL REIMBURSEMENT CPT CODES FOR MICROWAVE AND RADIOFREQUENCY ABLATION PROCEDURES IN US (EFFECTIVE JANUARY 1, 2022)
  • TABLE 14 TUMOR ABLATION MARKET: ROLE IN ECOSYSTEM
  • TABLE 15 AVERAGE SELLING PRICE OF TUMOR ABLATION SYSTEMS, BY REGION, 2021–2023
  • TABLE 16 IMPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2019–2023 (USD THOUSAND)
  • TABLE 17 EXPORT DATA FOR TUMOR ABLATION SYSTEMS (HS CODE 9018), BY COUNTRY, 2018–2022 (USD THOUSAND)
  • TABLE 18 PORTER’S FIVE FORCES ANALYSIS: TUMOR ABLATION MARKET
  • TABLE 19 LIST OF MAJOR CONFERENCES & EVENTS IN TUMOR ABLATION MARKET, 2024–2025
  • TABLE 20 CASE STUDY 1: RADIOFREQUENCY ABLATION ANALYSIS CASE STUDY
  • TABLE 21 CASE STUDY 2: ABLATION OF LOCALIZED RENAL TUMOR
  • TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
  • TABLE 23 KEY BUYING CRITERIA FOR TUMOR ABLATION SYSTEMS
  • TABLE 24 TUMOR ABLATION MARKET: CURRENT UNMET NEEDS
  • TABLE 25 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 26 RADIOFREQUENCY ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 27 MICROWAVE ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 28 CRYOABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 29 HIGH-INTENSITY-FOCUSED ULTRASOUND MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 30 OTHER TUMOR ABLATION TECHNOLOGIES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 31 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
  • TABLE 32 TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (UNITS)
  • TABLE 33 TUMOR ABLATION GENERATORS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 34 RADIOFREQUENCY ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 35 MICROWAVE ABLATION PROBES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 36 OTHER TUMOR ABLATION PROBES/ELECTRODES MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 37 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
  • TABLE 38 TUMOR ABLATION MARKET FOR SURGICAL ABLATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 39 TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 40 TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 41 TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 42 TUMOR ABLATION MARKET FOR LIVER CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 43 TUMOR ABLATION MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 44 TUMOR ABLATION MARKET FOR KIDNEY CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 45 TUMOR ABLATION MARKET FOR BONE CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 46 TUMOR ABLATION MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 47 TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 48 TUMOR ABLATION MARKET FOR HOSPITALS & CLINICS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 49 TUMOR ABLATION MARKET FOR CANCER CARE CENTERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 50 TUMOR ABLATION MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 51 TUMOR ABLATION MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 52 NORTH AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 NORTH AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 54 NORTH AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
  • TABLE 55 NORTH AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
  • TABLE 56 NORTH AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 57 NORTH AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 58 US: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 59 CANADA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 60 EUROPE: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 61 EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 62 EUROPE: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
  • TABLE 63 EUROPE: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
  • TABLE 64 EUROPE: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 65 EUROPE: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 66 GERMANY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 67 FRANCE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 68 UK: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 69 ITALY: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 70 SPAIN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 71 REST OF EUROPE: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 73 ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 74 ASIA PACIFIC: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 77 ASIA PACIFIC: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 78 JAPAN: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 79 CHINA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 80 INDIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 81 AUSTRALIA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 82 SOUTH KOREA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 83 REST OF ASIA PACIFIC: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 84 LATIN AMERICA: TUMOR ABLATION MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 85 LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 86 LATIN AMERICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
  • TABLE 87 LATIN AMERICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
  • TABLE 88 LATIN AMERICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 89 LATIN AMERICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 90 BRAZIL: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 91 MEXICO: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 92 REST OF LATIN AMERICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 93 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 94 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
  • TABLE 95 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2022–2029 (USD MILLION)
  • TABLE 96 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
  • TABLE 97 MIDDLE EAST & AFRICA: TUMOR ABLATION MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 98 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES
  • TABLE 99 TUMOR ABLATION TECHNOLOGY MARKET: DEGREE OF COMPETITION
  • TABLE 100 TUMOR ABLATION MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 101 TUMOR ABLATION MARKET: REGION FOOTPRINT
  • TABLE 102 TUMOR ABLATION MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS
  • TABLE 103 TUMOR ABLATION MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
  • TABLE 104 TUMOR ABLATION MARKET: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2024
  • TABLE 105 TUMOR ABLATION MARKET: DEALS, JANUARY 2021–MARCH 2024
  • TABLE 106 TUMOR ABLATION MARKET: EXPANSIONS, JANUARY 2021–MARCH 2024
  • TABLE 107 MEDTRONIC PLC: COMPANY OVERVIEW
  • TABLE 108 MEDTRONIC PLC: PRODUCTS OFFERED
  • TABLE 109 MEDTRONIC PLC: PRODUCT APPROVALS
  • TABLE 110 JOHNSON & JOHNSON MEDTECH: COMPANY OVERVIEW
  • TABLE 111 JOHNSON & JOHNSON MEDTECH: PRODUCTS OFFERED
  • TABLE 112 STRYKER CORPORATION: COMPANY OVERVIEW
  • TABLE 113 STRYKER CORPORATION: PRODUCTS OFFERED
  • TABLE 114 STRYKER CORPORATION: PRODUCT APPROVALS
  • TABLE 115 STRYKER CORPORATION: EXPANSIONS
  • TABLE 116 VARIAN MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW
  • TABLE 117 VARIAN MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED
  • TABLE 118 VARIAN MEDICAL SYSTEMS, INC.: PRODUCT LAUNCHES
  • TABLE 119 VARIAN MEDICAL SYSTEMS, INC.: DEALS
  • TABLE 120 ANGIODYNAMICS, INC.: COMPANY OVERVIEW
  • TABLE 121 ANGIODYNAMICS, INC.: PRODUCTS OFFERED
  • TABLE 122 ANGIODYNAMICS, INC.: DEALS
  • TABLE 123 BOSTON SCIENTIFIC CORPORATION: COMPANY OVERVIEW
  • TABLE 124 BOSTON SCIENTIFIC CORPORATION: PRODUCTS OFFERED
  • TABLE 125 EDAP TMS S.A.: COMPANY OVERVIEW
  • TABLE 126 EDAP TMS S.A.: PRODUCTS OFFERED
  • TABLE 127 MERMAID MEDICAL: COMPANY OVERVIEW
  • TABLE 128 MERMAID MEDICAL: PRODUCTS OFFERED
  • TABLE 129 CANYON MEDICAL INC.: COMPANY OVERVIEW
  • TABLE 130 CANYON MEDICAL INC.: PRODUCTS OFFERED
  • TABLE 131 OLYMPUS CORPORATION: COMPANY OVERVIEW
  • TABLE 132 OLYMPUS CORPORATION: PRODUCTS OFFERED
  • TABLE 133 OLYMPUS CORPORATION: PRODUCT LAUNCHES
  • TABLE 134 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: COMPANY OVERVIEW
  • TABLE 135 CHONGQING HAIFU MEDICAL TECHNOLOGY CO., LTD.: PRODUCTS OFFERED
  • TABLE 136 MERIT MEDICAL SYSTEMS, INC.: COMPANY OVERVIEW
  • TABLE 137 MERIT MEDICAL SYSTEMS, INC.: PRODUCTS OFFERED
  • TABLE 138 BIOVENTUS INC.: COMPANY OVERVIEW
  • TABLE 139 BIOVENTUS INC.: PRODUCTS OFFERED
  • TABLE 140 BIOVENTUS INC.: DEALS
  • TABLE 141 ICECURE MEDICAL LTD.: COMPANY OVERVIEW
  • TABLE 142 ICECURE MEDICAL LTD.: PRODUCTS OFFERED
  • TABLE 143 ICECURE MEDICAL LTD.: PRODUCT APPROVALS
  • TABLE 144 ICECURE MEDICAL LTD.: DEALS
  • TABLE 145 CONMED CORPORATION: COMPANY OVERVIEW
  • TABLE 146 CONMED CORPORATION: PRODUCTS OFFERED
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
  • FIGURE 5 TUMOR ABLATION MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
  • FIGURE 6 TUMOR ABLATION MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 7 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • FIGURE 9 TUMOR ABLATION MARKET, TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 10 TUMOR ABLATION MARKET, BY PRODUCT TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 TUMOR ABLATION MARKET, BY MODE OF TREATMENT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 TUMOR ABLATION MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 TUMOR ABLATION MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 TUMOR ABLATION MARKET: GEOGRAPHIC SNAPSHOT
  • FIGURE 15 RISING PREVALENCE OF CANCER TO DRIVE MARKET GROWTH
  • FIGURE 16 MICROWAVE ABLATION SEGMENT TO REGISTER SIGNIFICANT GROWTH IN NORTH AMERICA DURING FORECAST PERIOD
  • FIGURE 17 LIVER CANCER SEGMENT TO DOMINATE MARKET IN EUROPE DURING FORECAST PERIOD
  • FIGURE 18 HOSPITALS & CLINICS SEGMENT TO CONTINUE TO HOLD LARGEST SHARE IN ASIA PACIFIC MARKET
  • FIGURE 19 CHINA TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 20 TUMOR ABLATION MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 PREMARKET NOTIFICATION: 510(K) APPROVALS FOR MEDICAL DEVICES
  • FIGURE 22 CANADA: REGULATORY APPROVAL PROCESS FOR MEDICAL DEVICES
  • FIGURE 23 EUROPE: CE APPROVAL PROCESS FOR MEDICAL DEVICES
  • FIGURE 24 TUMOR ABLATION MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 25 TUMOR ABLATION MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 26 TUMOR ABLATION MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 27 NUMBER OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022
  • FIGURE 28 VALUE OF INVESTOR DEALS IN TUMOR ABLATION MARKET, BY KEY PLAYER, 2018–2022 (USD MILLION)
  • FIGURE 29 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY TECHNOLOGY
  • FIGURE 30 AVERAGE SELLING PRICE TREND OF TUMOR ABLATION SYSTEMS, BY REGION
  • FIGURE 31 PATENT DETAILS FOR TUMOR ABLATION MARKET (JANUARY 2013– DECEMBER 2023)
  • FIGURE 32 REVENUE SHIFT IN TUMOR ABLATION MARKET
  • FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES
  • FIGURE 34 KEY BUYING CRITERIA FOR PROCESS TUMOR ABLATION SYSTEMS
  • FIGURE 35 NORTH AMERICA: TUMOR ABLATION MARKET SNAPSHOT
  • FIGURE 36 ASIA PACIFIC: TUMOR ABLATION MARKET SNAPSHOT
  • FIGURE 37 REVENUE ANALYSIS OF TOP THREE PLAYERS IN TUMOR ABLATION MARKET (2021–2023)
  • FIGURE 38 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
  • FIGURE 39 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 40 TUMOR ABLATION MARKET: COMPANY FOOTPRINT
  • FIGURE 41 TUMOR ABLATION MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 42 EV/EBITDA OF KEY VENDORS
  • FIGURE 43 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 44 BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 45 MEDTRONIC PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 46 JOHNSON & JOHNSON MEDTECH: COMPANY SNAPSHOT (2022)
  • FIGURE 47 STRYKER CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 48 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 49 ANGIODYNAMICS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 51 EDAP TMS S.A.: COMPANY SNAPSHOT (2023)
  • FIGURE 52 OLYMPUS CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 53 MERIT MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022)
  • FIGURE 54 BIOVENTUS INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 55 ICECURE MEDICAL LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 56 CONMED CORPORATION: COMPANY SNAPSHOT (2023)

The study involved four major activities in estimating the current size of the tumor ablation market. Exhaustive secondary research was done to collect information on the market, peer, and parent markets. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

Secondary Research

The secondary research process involves the widespread use of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B Hoovers), white papers, annual reports, company house documents, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial tumor ablation market study. It was also used to obtain important information about the key players and market classification & segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives. A database of the key industry leaders was also prepared using secondary research.

Primary Research

In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, and related key executives from various key companies and organizations in the tumor ablation market. The primary sources from the demand side include hospitals, clinics, retailers, and other end users. Primary research was conducted to validate the market segmentation, identify key players, and gather insights on key industry trends & key market dynamics.  

A breakdown of the primary respondents is provided below:

Tumor Ablation Market Size, and Share

*Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The tiers of the companies are defined based on their total revenue. As of 2023: Tier 1 => USD 1 billion, Tier 2 = USD 200-500 million to USD 1 billion, and Tier 3 =< USD 200 million

To know about the assumptions considered for the study, download the pdf brochure

Market Estimation Methodology

In this report, the tumor ablation market’s size was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the market business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key marketing executives.

Segmental revenues were calculated based on the revenue mapping of major solution/service providers to calculate the global market value. This process involved the following steps:

  • Generating a list of major global players operating in the tumor ablation market.
  • Mapping annual revenues generated by major global players from the product segment (or nearest reported business unit/product category)
  • Revenue mapping of major players to cover a major share of the global market share, as of 2022
  • Extrapolating the global value of the tumor ablation market industry

Bottom-up approach

In this report, the size of the global tumor ablation market was determined using the revenue share analysis of leading players. For this purpose, key players in the market were identified, and their revenues from the tumor ablation business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and marketing executives.

Approach 1: Company revenue estimation approach

To calculate the global market value, segmental revenues were calculated based on the revenue mapping of major solution/product providers. This process involved the following steps:

  • Generating a list of major global players operating in the tumor ablation market
  • Mapping the annual revenues generated by major global players from the tumor ablation segment (or the nearest reported business unit/product category)
  • Mapping the revenues of major players to cover at least 50-55% of the global market share as of 2023
  • Extrapolating the global value of the tumor ablation industry

Market Size Estimation For Tumor Ablation: Approach 1 (Company Revenue Estimation)I

Tumor Ablation Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Approach 2: Customer-based market estimation

During preliminary secondary research, the total sales revenue of tumor ablation was estimated and validated at the regional and country level, triangulated, and validated to estimate the global market value. This process involved the following steps:

  • Generating a list of major customer facilities across each region and country
  • Identifying the average number of tumor ablation product supplies used by major customer facilities across each product type at the regional/country level, annually
  • Identifying the percentage contribution of major customer facilities to the overall tumor ablation expenditure and usage at the regional/country level, annually
  • Extrapolating the annual usage patterns for various products across major customer facilities to estimate the size of each product segment at the regional/country level, annually
  • Identifying the percentage contributions of individual market segments and subsegments to the overall tumor ablation market at the regional/country level

Tumor Ablation Market Size Estimation: Bottom-Up Approach

Tumor Ablation Market Size, and Share

Source: MarketsandMarkets Analysis

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the global tumor ablation market was split into segments and subsegments. Data triangulation and market breakdown procedures were employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments. The data was triangulated by studying various factors and trends from both the demand and supply sides. Additionally, the tumor ablation market was validated using top-down and bottom-up approaches.

Market Definition

Tumor ablation is a minimally invasive surgical procedure used to remove or destroy cancerous tissue from the affected area as part of cancer management and treatment. The targeted tissue is subjected to ablating energy through surgical, laparoscopic, or percutaneous methods. This technique is commonly used for treating liver, bone, lung, kidney, prostate, and other types of cancer.

Key Stakeholders

  • Tumor ablation product manufacturers
  • Original equipment manufacturers (OEMs)
  • Suppliers, distributors, and channel partners
  • Healthcare service providers
  • Hospitals and academic medical centers
  • Interventional radiologists
  • Research laboratories
  • Health insurance providers
  • Government bodies/organizations
  • Regulatory bodies
  • Medical research institutes
  • Business research and consulting service providers
  • Venture capitalists and other public-private funding agencies
  • Market research and consulting firms

Objectives of the Study

  • To define, describe, and forecast the tumor ablation market based on technology, product type, mode of treatment, application, end user, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze micro markets with respect to individual growth trends, prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the revenue of the market segments with respect to five regions, namely, North America, Europe, the Asia Pacific, Latin America, Middle East and Africa
  • To profile the key players and comprehensively analyze their market ranking and core competencies
  • To benchmark players within the market using a proprietary competitive leadership mapping framework, which analyzes market players on various parameters within the broad categories of  market share and product footprint

Available Customizations

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the present global tumor ablation market report:

Product Analysis

  • Product matrix, which gives a detailed comparison of the product portfolios of the top five companies

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Geographic Analysis

  • Further breakdown of the Rest of Europe tumor ablation market into Russia, Belgium, the Netherlands, Switzerland, Austria, Finland, Sweden, Poland, and Portugal, among others
  • Further breakdown of the Rest of Asia Pacific tumor ablation market into Singapore, Taiwan, New Zealand, Philippines, Malaysia, and other APAC countries
  • Further breakdown of the Rest of Latin America (RoLATAM), which comprises Argentina, Chile, Peru, Colombia, and Cuba
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
MD 3271
Published ON
May, 2024
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Tumor Ablation Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
knowledgestore logo

Want to explore hidden markets that can drive new revenue in Tumor Ablation Market?

Find Hidden Markets
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status
Website Feedback